AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

NCT00075335 | Completed Phase 2 Results

• 2 other identifiers: 04007804-H-0078
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

Peripheral blood progenitor cells (PBPC) have become the preferred source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and shorter time required for engraftment. Traditionally, granulocyte-colony stimulating factor (G-CSF) has been used to procure the peripheral blood stem cell graft. Although regimens using G-CSF usually succeed in collecting adequate numbers of PBPC from healthy donors, 5%-10% will mobilize stem cells poorly and may require multiple large volume apheresis or bone marrow harvesting. Although G-CSF is generally well tolerated in healthy donors, it may be associated with bone pain, headache, myalgia and rarely life threatening side effects like stroke, myocardial infarction and splenic rupture. AMD3100, is a bicyclam compound that inhibits the binding of stromal cell derived factor-1 (SDF-1) to its cognate receptor CXC- chemokine receptor 4 (CXCR4). CXCR4 is present on cluster of differentiation 34 (CD34)+ hematopoetic progenitor cells and its interaction with stromal cell derived factor 1 (SDF-1) plays a pivotal role in the homing of CD34+ cells in the bone marrow. Inhibition of the CXCR4-SDF1 axis by AMD3100 releases CD34+ cells into the circulation, which can then be collected easily by apheresis. Recently, a published report demonstrated that large numbers of CD34+ cells were rapidly mobilized in healthy volunteers following a single subcutaneous injection of AMD3100. Remarkably, the number of CD34+ cells collected by apheresis following a single injection of AMD3100 was comparable to the number of CD34+ cells collected from historical controls receiving 5 days of G-CSF prior to stem cell mobilization. In this study we will collect PBPCs following a single subcutaneous injection of AMD3100 from healthy donors who have previously had PBPC collected using standard G-CSF mobilization. The AMD3100 mobilized cells, G-CSF mobilized cells, and circulating cells prior to both AMD3100 and G-CSF mobilization will be analyzed in terms of cellular content and function of lymphocytes, natural killer (NK) cells, and antigen presenting cells. AMD3100 mobilized PBPC will be collected for the purpose of research studies and will not be used for therapeutic purposes.

Conditions

Healthy

Keywords

Hematopoietic Stem Cells; Mobilization; Alloreactivity; T Cell Polarization; Dendritic Cells; Plerixafor; Mozobil; Healthy Volunteer (HV)

Outcome Measures

Primary Outcomes (2)

• Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following G-CSF Administration

  Examine G-CSF mobilization effect on cytokine polarization of T-cells. Analyze cytokine gene expression profiles using a Th1-Th2-Th3 RT-PCR plate in CD3+ T cells collected form subjects mobilized with 5 injections of G-CSF. 84 cytokine genes were analyzed for significant alteration in their profiles.

  1 Day

• Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following Plerixafor Administration

  Examine plerixafor mobilization effect on cytokine polarization of T-cells. Analyze cytokine gene expression profiles using a Th1-Th2-Th3 RT-PCR plate in CD3+ T cells collected form subjects mobilized with a single injection of plerixafor. 84 cytokine genes were analyzed for significant alteration in their profiles.

  1 Day

Study Arms (1)

AMD 3100 (Mozobil plerixafor)

EXPERIMENTAL

AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.

Drug: AMD3100 (Mozobil plerixafor)

Interventions

AMD3100 (Mozobil plerixafor) DRUG

AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.

Also known as: Mozobil plerixafor

AMD 3100 (Mozobil plerixafor)

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Mobilization and collection of PBPC using G-CSF at least 60 days prior to protocol enrollment (stem cell donors enrolled on Branch transplant protocols or healthy volunteers enrolled on 96-H-0049: Use of granulocyte colony stimulating factor mobilized leukapheresis collections from healthy volunteers).
• Ages greater than or equal to 18 years and less than or equal to 80 years.
• Normal renal function: creatinine less than 1.5 mg/dl.
• Normal liver function: total bilirubin less than 1.5mg/dl, alanine aminotransferase (ALT) 6 -41 U/L, aspartate aminotransferase (AST) 9-34 U/L.
• Normal blood count: white blood cell (WBC) 3000-10000/mm(3)
• granulocytes greater than 1500/mm(3)
• platelets greater than 150,000/mm(3)
• hemoglobin (females greater than 11.1 g/dl, males greater than 12.7 g/dl).
• Subject must be eligible for normal blood donation and fit to undergo apheresis procedure (antecubital veins must be adequate for peripheral access during apheresis).
• Ability to comprehend the investigational nature of the study and provide informed consent.

You may not qualify if:

• Active infection or history of recurrent infection- hepatitis B and C (HBsAg, Anti-HBc, Anti-HCV), HIV and human T- lymphocytic virus (HTLV-1).
• History of autoimmune disease such as rheumatoid arthritis, systemic lupus erythematous.
• History of cancer within the past 5 years excluding basal cell or squamous cell carcinoma of the skin.
• History of any hematologic disorders including thromboembolic disease.
• History of cardiac disease such as uncontrolled hypertension, peripheral vascular disease, myocardial infarction, cardiac arrhythmias OR related symptoms such as tachycardia, chest pain, shortness of breath which have required medical intervention OR treatment or a Framingham coronary disease risk prediction score of greater than 10% 10 year coronary heart disease (CHD) risk.
• History of cerebrovascular disease, transient ischemic attack, or stroke.
• Pregnant or lactating.
• Severe psychiatric illness: mental deficiency sufficiently severe as to make informed consent impossible

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (4)

• Mohle R, Murea S, Kirsch M, Haas R. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol. 1995 Dec;23(14):1535-42.

  PMID: 8542944 BACKGROUND

• Mohle R, Haas R, Hunstein W. Expression of adhesion molecules and c-kit on CD34+ hematopoietic progenitor cells: comparison of cytokine-mobilized blood stem cells with normal bone marrow and peripheral blood. J Hematother. 1993 Winter;2(4):483-9. doi: 10.1089/scd.1.1993.2.483.

  PMID: 7522108 BACKGROUND

• Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002 Jul;3(7):687-94. doi: 10.1038/ni813. Epub 2002 Jun 17.

  PMID: 12068293 BACKGROUND

• Lundqvist A, Smith AL, Takahashi Y, Wong S, Bahceci E, Cook L, Ramos C, Tawab A, McCoy JP Jr, Read EJ, Khuu HM, Bolan CD, Joo J, Geller N, Leitman SF, Calandra G, Dunbar C, Kurlander R, Childs RW. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol. 2013 Dec 15;191(12):6241-9. doi: 10.4049/jimmunol.1301148. Epub 2013 Nov 15.

  PMID: 24244025 RESULT

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Interventions

plerixafor

Results Point of Contact

• Title: Dr. Richard Childs
• Organization: NHLBI NIH

childsr@nhlbi.nih.gov

301-594-8008

Study Officials

• Richard W Childs, M.D.

  National Heart, Lung, and Blood Institute (NHLBI)

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Hematology Clinician

Study Record Dates

• First Submitted: January 8, 2004
• First Posted: January 9, 2004
• Study Start: January 1, 2004
• Primary Completion: August 1, 2012
• Study Completion: August 1, 2012
• Last Updated: February 7, 2018
• Results First Posted: February 7, 2018

Record last verified: 2018-02

Locations

US (1)